<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003741</url>
  </required_header>
  <id_info>
    <org_study_id>BIDMC-97127</org_study_id>
    <secondary_id>CDR0000066859</secondary_id>
    <secondary_id>NEDH-97127</secondary_id>
    <secondary_id>NCI-870</secondary_id>
    <secondary_id>NCI-V99-1515</secondary_id>
    <nct_id>NCT00003741</nct_id>
  </id_info>
  <brief_title>Monoclonal Antibody Therapy in Treating Patients With Refractory Anaplastic Large Cell Lymphoma or Hodgkin's Lymphoma</brief_title>
  <official_title>HeFi-1 Antibody Therapy in Ki-1 and Hodgkin's Lymphomas, a Phase I Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver&#xD;
      cancer-killing substances to them without harming normal cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy in treating&#xD;
      patients with refractory anaplastic large cell lymphoma or Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety and tolerability of multiple doses of monoclonal antibody HeFi-1 in&#xD;
           patients with CD30+ anaplastic large cell lymphoma or Hodgkin's lymphoma.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this drug in this patient population.&#xD;
&#xD;
        -  Evaluate the efficacy, in terms of correlating immunologic parameters and&#xD;
           immunogenicity, of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, dose-escalation study.&#xD;
&#xD;
      Patients receive monoclonal antibody HeFi-1 IV over 30 minutes 3 times a week for 2 weeks.&#xD;
      Treatment may continue for 2 additional weeks in the absence of anti-HeFi-1 response.&#xD;
      Responding patients may continue treatment at monthly intervals for one year.&#xD;
&#xD;
      Cohorts of 3-4 patients receive escalating doses of monoclonal antibody HeFi-1 until the&#xD;
      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at&#xD;
      which 2 of 4 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed monthly.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 9 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 1999</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>monoclonal antibody HeFi-1</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed CD30+ anaplastic large cell lymphoma (ALCL) or Hodgkin's&#xD;
             lymphoma&#xD;
&#xD;
               -  At least 50% of malignant cells must react with HeFi-1&#xD;
&#xD;
               -  HIV positive or HIV negative&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  No symptomatic CNS disease&#xD;
&#xD;
          -  Must have failed or be ineligible for standard chemotherapy regimen&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 2 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  No significant hepatic disease&#xD;
&#xD;
          -  Bilirubin no greater than 2 mg/dL&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  No significant renal disease&#xD;
&#xD;
          -  Creatinine no greater than 3 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No significant cardiovascular disease&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No significant pulmonary disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No significant endocrine, rheumatologic, or allergic disease&#xD;
&#xD;
          -  No active clinical disease caused by cytomegalovirus (CMV), herpes simplex virus (HSV)&#xD;
             I, HSV II, hepatitis B, or tuberculosis&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior murine antibody therapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy to measurable disease&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 4 weeks since prior cytotoxic therapy to measurable disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henry Koon, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2005</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 25, 2013</last_update_submitted>
  <last_update_submitted_qc>June 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2013</last_update_posted>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

